Skip to main content

ResearchResearch summary

Candida biofilm findings in recurrent vaginal yeast infection

Isolates from recurrent vaginal yeast infections had higher biomass in vitro; XTT and confocal comparisons were not significant; no treatment was tested.

In this pathway

Current topic
Candida biofilm findings in recurrent vaginal yeast infectionCurrent

Page trust and updates

First published
2026-10-09
Evidence as of
2026-10-09
Last updated
2026-10-09
Authorship
Candipedia Research
What changed
Added a contextual summary of a prospective vaginal-isolate study; its assay findings do not establish an in-vivo biofilm, causation, or treatment benefit, and practical guidance is unchanged.
Mogana Das Murtey and Patchamuthu Ramasamy, "Saccharomyces cerevisiae, SEM image", licensed under CC BY 3.0

Sources behind these conclusions

Bottom line

This prospective cohort found higher in-vitro crystal-violet biofilm biomass among vaginal Candida isolates from the RVVC group than the non-RVVC group. XTT activity and the smaller confocal-area comparison were not significantly different, and no treatment was tested.

Why this source matters

The study connects patient-reported recurrence status with laboratory measurements from vaginal Candida isolates. It adds a prospective clinical-isolate comparison to biofilm research, while keeping the measured phenotype separate from biofilm burden in a person's vagina or any treatment effect.

Study and population

This prospective observational study enrolled 271 adults with Candida spp. recovered from vaginal swabs at the sexually transmitted diseases consultation service of a tertiary teaching hospital in Madrid, Spain. The median age was 34 years (IQR 26–45). Nineteen patients were classified as having recurrent vulvovaginal candidiasis (RVVC) and 252 as non-RVVC. Participants were enrolled from October 2021 to October 2022 and followed for another year, through October 2023. The RVVC group definition was at least 3 symptomatic episodes in a year, but not every episode was culture-confirmed.

What was tested

Researchers tested the first vaginal Candida isolate recovered from each patient. Crystal-violet absorbance measured biomass and XTT absorbance measured metabolic activity after 24 hours in a laboratory biofilm model, with triplicate assays. Confocal microscopy measured the area occupied by biofilm in 16 RVVC isolates and 16 arbitrarily selected, species-matched non-RVVC isolates. No biofilm-disrupting product, antifungal regimen, or other intervention was assigned.

Results

Fifty-five of 271 patients (20.3%) reported at least one recurrence; 19/271 (7.0%) met the study's RVVC-group definition and reported 65 episodes.

For crystal-violet biomass, 18/19 RVVC isolates had a median absorbance of 1.850 (IQR 1.578–2.156), compared with 1.426 (1.081–1.823) among 238/252 non-RVVC isolates (p=0.005). For XTT metabolic activity, the same 18/19 and 238/252 isolates had medians of 0.184 (0.116–0.293) and 0.228 (0.147–0.331), respectively (p=0.253); this difference was not statistically significant.

Confocal area was assessed in 16/19 RVVC isolates and 16 selected, species-matched non-RVVC isolates. Median occupied area was 13.15% (IQR 8.54–16.49) versus 10.73% (5.88–17.73) (p=0.710), also not statistically significant. C. albicans accounted for 90.0% of isolates overall; it was reported in 73.7% of RVVC and 91.3% of non-RVVC isolates (p=0.029). One abstract sentence gives 73.3% for the RVVC group, while the Results and Table 1 give 73.7%; this summary uses the Results and Table 1 value.

The overall symptom comparison was not significant (p=0.258), and prior antifungal use was 5/19 versus 33/252 (p=0.160). Neither comparison estimates a treatment effect.

Applicability

The findings apply to group-level associations between in-vitro measurements of vaginal Candida isolates and reported RVVC status in this adult, single-center Spanish cohort. They do not show how much biofilm was present in a person's vagina, explain an individual's recurrence, identify treatment failure or resistance, or support broad intestinal or whole-body Candida claims.

Limitations

Only 19 patients were in the RVVC group, and the study reported no sample-size calculation or prespecified primary outcome. Classification relied mainly on reported symptoms; not every episode was culture-confirmed. CV and XTT assays included 256/271 isolates (18/19 RVVC and 238/252 non-RVVC), while confocal microscopy included 16/19 RVVC isolates and 16/252 arbitrarily selected, species-matched non-RVVC isolates. The 24-hour laboratory measurements are not in-vivo vaginal biofilm measurements. The study did not test a disruptor or treatment and cannot establish cause, diagnosis, prognosis, or treatment benefit. E. coli co-isolation was assessed in only 81/271 samples, with no RVVC samples available for that test. Table 1's total count for moderate symptoms conflicts with its component counts, so no total is inferred.

Contribution to the evidence

Contextual. The cohort adds a prospective patient-level comparison in which in-vitro crystal-violet biomass was higher among RVVC isolates, but XTT activity and the selected confocal-area comparison were not significantly different. It informs the defined mucosal context without measuring biofilm in vivo or changing the linked map's verdict, evidence level, safety status, or practical action.

Practical change

No practical change. The study did not evaluate an intervention, diagnostic test, or care route. Its isolate-assay association is not a reason to add a biofilm disruptor or change treatment.

Funding and conflicts

Funding came from Fundación Mutua Madrileña (FMM24/01), IiSGM (2022-PI-II-COOPTR-01), and ISCIII/FEDER (PI21/00344), with named Miguel Servet and ISCIII support for M. Guembe, P. Escribano, and M. Díaz-Navarro. JG reported speaking and lecture fees from Pfizer, Gilead Sciences, and Merck Sharp & Dohme UK. Other authors reported no commercial or financial relationships that could be construed as conflicts. One author disclosed Frontiers editorial-board membership at submission and stated it did not affect peer review.

Source

Read the original publication (published 27 March 2025; Frontiers in Microbiology. 2025;16:1566171).

Study type, population, and sample scale

Study type
Prospective single-center observational clinical-isolate cohort with in-vitro biofilm assays
Population
Adults aged 18 years or older with Candida spp. recovered from vaginal swabs at a tertiary teaching hospital in Madrid, Spain; recurrent vulvovaginal candidiasis (RVVC) classification used reported symptomatic episodes and did not verify every episode by culture.
Sample scale
271 patients (19 RVVC and 252 non-RVVC); CV/XTT assays included 18/19 and 238/252 isolates; CLSM included 16/19 RVVC isolates and 16 selected non-RVVC isolates.
Read the original source

Results

  • Of 271 patients, 19/271 (7.0%) met the study RVVC-group definition; 55/271 (20.3%) reported at least one recurrence, and the RVVC group reported 65 episodes. The study used at least 3 symptomatic episodes per year, but not every episode had culture confirmation.
  • Crystal-violet biomass was measured in 18/19 RVVC isolates and 238/252 non-RVVC isolates. Median absorbance was 1.850 (IQR 1.578–2.156) versus 1.426 (1.081–1.823), respectively (p=0.005).
  • XTT metabolic activity used the same denominators: 18/19 versus 238/252. Median absorbance was 0.184 (IQR 0.116–0.293) versus 0.228 (0.147–0.331) (p=0.253), a nonsignificant difference.
  • Confocal microscopy measured occupied area in 16/19 RVVC isolates and 16 arbitrarily selected, species-matched non-RVVC isolates. Median area was 13.15% (IQR 8.54–16.49) versus 10.73% (5.88–17.73) (p=0.710), not a statistically significant difference.
  • C. albicans accounted for 90.0% of isolates overall and 73.7% in the RVVC group versus 91.3% in the non-RVVC group (p=0.029). One abstract sentence reports 73.3%; the Results and Table 1 report 73.7%, used here.
  • Overall symptom categories did not differ significantly between groups (p=0.258); prior antifungal use was 5/19 versus 33/252 (p=0.160). These are descriptive group comparisons, not treatment effects.

Limitations

The study classified 19 patients as RVVC and followed the clinical-isolate cohort at one tertiary hospital in Madrid.
It was a small, single-center observational study without a reported sample-size calculation or prespecified primary outcome; episode classification relied mainly on patient reports and not every episode was culture-confirmed.
Biofilm biomass and metabolic activity were measured after 24 hours using the first recovered isolate per patient; confocal area was measured in 32 isolates.
These in-vitro assays do not measure biofilm in the vagina, establish causation, show diagnostic performance, or test treatment. The non-RVVC confocal subset was arbitrarily selected and species-matched.
CV and XTT assays included 256/271 isolates (18/19 RVVC and 238/252 non-RVVC); confocal microscopy included 16/19 RVVC and 16/252 selected non-RVVC isolates.
Isolates were unavailable for CV/XTT in 15/271 patients, and the smaller confocal subset may not represent either group. E. coli co-isolation was assessed in only 81/271 samples, with no RVVC samples available for that test.
Table 1 reports moderate symptoms in 6/19 RVVC and 37/252 non-RVVC patients, while its total count is inconsistent with those component counts.
Do not infer a total moderate-symptom count from that table. The abstract also has one conflicting C. albicans percentage; the Results and Table 1 report 73.7% for RVVC, used in this summary.

Applies to

  • Group-level associations between in-vitro biofilm measurements from vaginal Candida isolates and reported RVVC status in this adult Spanish clinic cohort

Does not apply to

  • Biofilm burden measured in a person's vagina; an individual diagnosis, prognosis, or explanation for recurrence; treatment failure or antifungal resistance; benefit or safety of a biofilm-disrupting product; broad intestinal or whole-body Candida claims

Contribution to the current conclusion

Contextual

The cohort adds a prospective human vaginal-isolate comparison to the defined-site biofilm evidence. Crystal-violet biomass was higher in the RVVC group, while XTT metabolic activity and the selected confocal-area comparison were not significantly different. These 24-hour in-vitro assays do not measure vaginal biofilm burden in vivo, establish that biofilm causes recurrence, test a disruptor, or change practical guidance.

Related evidence map

Practical change or no change

No practical change. The study adds a limited in-vitro association between isolate biomass and reported RVVC status, but does not establish an in-vivo vaginal biofilm, causation, diagnosis, treatment benefit, or a reason to change care.

Funding and conflicts

Funding
The study was funded by Fundación Mutua Madrileña (FMM24/01), IiSGM (2022-PI-II-COOPTR-01), and ISCIII/FEDER (PI21/00344). Miguel Servet support (MSII18/00008) supported M. Guembe and (CPII20/00015) supported P. Escribano; M. Díaz-Navarro received ISCIII support (FI22/00022).
Conflicts
JG reported speaking and lecture fees from Pfizer, Gilead Sciences, and Merck Sharp & Dohme UK. The other authors reported no commercial or financial relationships that could be construed as conflicts. One author disclosed Frontiers editorial-board membership at submission and stated it did not affect peer review.
Paper date
2025-03-27

Sources

View all 1 source